Anemias Archives - Page 21 of 22 - MPR

Anemias

First Prospective Randomized Study Demonstrates Safety, Efficacy of Transfusion Therapy in Adults With Sickle Cell Disease

Transfusion therapy in adults with sickle cell disease (SCD) is safe and improves or stabilizes critical laboratory markers, decreases serious sickle cell anemia-related adverse events, and decreases hospitalizations, preliminary data from the first prospective randomized study of the safety and efficacy of transfusion therapy in adults with SCD has found. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Iron Supplementation of Erythropoiesis-Stimulating Agents Increases Hematopoietic Response Rates in Patients With Cancer and Chemotherapy-Induced Anemia

When compared with using erythropoiesis-stimulating agents (ESA) alone or placebo, iron supplementation of ESAs significantly increases hematopoietic response rates and reduces the number of red blood cell (RBC) transfusions in patients with chemotherapy-induced anemia (CIA), results of the first systematic review and meta-analysis have found. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Amgen recalls certain lots of Epogen and Procrit

Amgen and Centocor Ortho Biotech announced a voluntary nationwide recall of certain lots of Epogen (epoetin alfa) and Procrit (epoetin alfa) vials that may contain extremely thin glass flakes (lamellae) that are barely visible in most cases.